Q-omics provides the consensus-scored LINC01185 profile across patient tissues and cancer cell-line models. LINC01185 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01185 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, LINC01185 RNA expression shows 12,351 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where LINC01185 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01185 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01185 survival associations across molecular data types. LINC01185 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01185 RNA expression–survival associations across cancer types. High LINC01185 expression shows unfavorable associations in KIRC, KICH, ACC, CESC and LIHC, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01185 RNA expression.
This table summarizes LINC01185 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01185. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01185 shows lower tumor expression in THCA and KICH and higher tumor expression in BRCA, LUAD, LIHC and BLCA. The THCA box plot shows higher LINC01185 RNA expression in normal versus tumor tissue (log2 FC = −0.074, t-test p = .001).
This table shows molecular features associated with LINC01185 in patient tissues and cancer cell lines. In patient samples, LINC01185 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
